Trial reportThe oncologist2014
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
3 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph
Trial report in The oncologist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 62 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 4 pooled it
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients Ineligible for Curative Resection or Local Treatment
The Clinical Randomized Trial of Adjuvant Chemotherapy With FOLFOX in HCC Patients at High Risk After Resection
NCT07746960 early_phase1active not recruitingnot on this mapstarted 2025, after this paper: background citation
A Single-center Exploratory Clinical Study of Chemotherapy With the Ralox Regimen Combined With Anlotinib and Penpulimab for Unresectable Hepatocellular Carcinoma
Who cites it
62 citing papers in PubMed, 4 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic review.Frontiers in immunology · 2025Pooled it
- 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.Korean journal of radiology · 2019Guideline
- 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.Gut and liver · 2019Guideline
- Pooled it
- Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study.Drug design, development and therapy · 2021Trial
- Sorafenib alone vs. sorafenib plus GEMOX as 1British journal of cancer · 2019Trial
- Self-Assembly of Stimuli-Responsive Peptide Enhances Therapeutics by Specifically Disrupting Hepatocellular Carcinoma Lysosomes In Vivo.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Koumine's Therapeutic Impact on Hepatocellular Carcinoma: A Combined Network Pharmacology and Experimental Study.Biomedicines · 2026Article
- China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).Liver cancer · 2025Article
- Article
- Deciphering hypoxia's role in hepatocellular carcinoma prognosis with single-cell approaches.Discover oncology · 2025Article
- Sorafenib with or without co-interventions for hepatocellular carcinoma.The Cochrane database of systematic reviews · 2025Review
- Molecular Subtyping of Hepatocellular Carcinoma via Lysosome-Related Genes for Prognosis and Therapy Prediction.International journal of general medicine · 2025Article
- Relationships Among Serological Indicators andCombinatorial chemistry & high throughput screening · 2025Article
- Article
- Clinical features and prognostic factors of patients with inoperable hepatocellular carcinoma treated with chemotherapy: a population-based study.Journal of gastrointestinal oncology · 2024Article
- Chinese expert consensus on refined diagnosis, treatment, and management of advanced primary liver cancer (2023 edition).Liver research (Beijing, China) · 2024Article
- [Drug research and development and unmet needs for advanced-stage hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- The Performance of a Survival Nomogram and Albumin-Bilirubin Grade as Prognostic Tools in Advanced Hepatocellular Carcinoma Treated with FOLFOX4.Journal of personalized medicine · 2024Article
- LABS score- a prognostic tool for FOLFOX4-treated advanced hepatocellular carcinoma and real-world efficacy: a single-center retrospective study.BMC cancer · 2024Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 14 institutions in 2 countries.
Shukui QinPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China qinsk@csco.org.cn.
Ying ChengPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Jun LiangPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Lin ShenPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Yuxian BaiPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Jianfeng LiPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Jia FanPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Lijian LiangPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Yaqi ZhangPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Gang WuPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Kun-Ming RauPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Tsai-Shen YangPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Zhixiang JianPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Houjie LiangPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
Yan SunPeople's Liberation Army Cancer Center, Bayi Hospital, Nanjing, People's Republic of China; Department of Medical Oncology, Jilin Province Cancer Hospital, Changchun, People's Republic of China; Department of Medical Oncology, The Affiliated Hospital of Medical College Qingdao University, Qingdao, People's Republic of China; Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing, People's Republic of China; Department of Medical Oncology, Heilongjiang Province Cancer Hospital, Harbin, People's Republic of China; Medical Affairs, Sanofi China, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, Zhong Shan Hospital, Shanghai, People's Republic of China; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China; Department of Interventional Radiology, Sun Yat-sen University Cancer Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Wuhan Union Hospital, Hubei, People's Republic of China; Department of Medical Oncology, Kaohsiung Chang-Gung Memorial Hospital, Kaohsiung, Taiwan, Republic of China; LinKou Medical Center, Chang-Gung Memorial Hospital, Taoyuan, Taiwan, Republic of China; Department of Hepatobiliary Surgery, Guangdong General Hospital, Guangzhou, People's Republic of China; Department of Medical Oncology, Southwest Hospital, Chongqing, People's Republic of China; Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China.
81th Hospital of PLA · CNChang Gung Memorial Hospital · TWChinese Academy of Medical Sciences & Peking Union Medical College · CNGuangdong General Hospital · CNHarbin Medical University · CNJilin Province Tumor Hospital · CNKaohsiung Chang Gung Memorial Hospital · TWPeking University · CNQingdao University · CNSanofi (China) · CNSouthwest Hospital · CNSun Yat-sen University · CNSun Yat-sen University Cancer Center · CNWuhan Union Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe EACH study assessed the efficacy of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen) compared with doxorubicin alone in terms of overall survival (OS), progression-free survival (PFS), and safety in patients with advanced hepatocellular carcinoma (HCC). We present the results of this study in Chinese patients.
methodsIn a multicenter, open-label, randomized, phase III study (NCT00471965), 371 patients (279 patients from the People's Republic of China) were randomized 1:1 to receive either FOLFOX4 or doxorubicin until disease progression, intolerable toxicity, death, or surgical resection.
resultsBaseline characteristics of the Chinese patients enrolled in the study were similar for the 2 treatment groups and in comparison with the whole EACH cohort. Median OS at the prespecified time point of treatment was 5.7 months with FOLFOX4 and 4.3 months with doxorubicin (hazard ratio [HR]: 0.74; 95% confidence interval [CI]: 0.55-0.98; p = .03). At the end of the follow-up period, median OS was 5.9 months with FOLFOX4 and 4.3 months with doxorubicin (HR: 0.75; 95% CI: 0.58-0.98; p = .03). Median PFS was 2.4 months and 1.7 months in the FOLFOX4 and doxorubicin groups, respectively (HR: 0.55; 95% CI: 0.45-0.78; p = .0002). The response rate (RR) and disease control rate (DCR) were significantly higher in the FOLFOX4 group than in the doxorubicin group (RR: 8.6% vs. 1.4%, p = .006; DCR: 47.1% vs. 26.6%, p = .0004). Hematological toxicity was more frequently reported in the FOLFOX4 group.
conclusionFor Chinese HCC patients enrolled in the EACH study, FOLFOX4 significantly improved the RR and DCR and prolonged survival compared with doxorubicin. Systemic chemotherapy with oxaliplatin-based regimens may play an important role in the treatment of Chinese patients with advanced HCC.
Indexed as
AdultAntineoplastic Combined Chemotherapy ProtocolsAsian PeopleCarcinoma, HepatocellularDoxorubicinFemaleFluorouracilHumansLeucovorinLiver NeoplasmsMaleMiddle AgedOrganoplatinum CompoundsSurvival AnalysisTreatment OutcomeDoxorubicinFluorouracilLeucovorinOrganoplatinum CompoundsFOLFOX4 regimenHepatocellular carcinomaOxaliplatinSystemic chemotherapy
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.